ログイン
ランキング
お知らせ
ログイン
文献詳細
特集 Common diseaseは神経学の主戦場である—revisited
文献概要
脳神経内科医が診療する中で，頭痛は最も多く遭遇する疾患の1つであるが，患者の苦痛にもかかわらず，一次性頭痛の片頭痛は生命に危険が及ぶわけでもなく，検査も異常がないので鎮痛薬などでやり過ごすことが多かった。しかし，CGRP関連抗体製剤の登場により，片頭痛治療も変化し始めている。いまだに多くの片頭痛患者が医療機関を受診せず，適切な治療を受けていない。今後，頭痛医療をさらに推進していく必要がある。
参考文献
1）Li XY, Yang CH, Lv JJ, Liu H, Zhang LY, et al: Correction: global, regional, and national epidemiology of migraine and tension-type headache in youths and young adults aged 15-39 years from 1990 to 2019: findings from the global burden of disease study 2019. J Headache Pain 24: 156, 2023［doi: 10.1186/s10194-023-01693-z］
2）World Health Organization: Atlas: country resources for neurological disorders, 2nd ed. https://www.who.int/publications/i/item/9789241565509（最終閲覧日: 2024年5月1日）
3）World Health Organization: Lifting the burden: Atlas of headache disorders and resources in the world 2011. 2011 https://www.who.int/publications/i/item/9789241564212（最終閲覧日: 2024年5月1日）
4）Göbel H: Classification of headaches. Cephalalgia 21: 770-773, 2001
5）Nappi G, Agnoli A, Manzoni GC, Nattero G, Sicuteri F: Classification and diagnostic criteria for primary headache disorders (Ad Hoc Committee IHS, 1988). Funct Neurol 4: 65-71, 1989
6）Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders: 2nd ed. Cephalalgia 24 Suppl 1: 9-160, 2004
7）Headache Classification Committee of the International Headache Society (IHS): The International Classification of Headache Disorders, 3rd ed (beta version). Cephalalgia 33: 629-808, 2013
8）Headache Classification Committee of the International Headache Society (IHS): The International Classification of Headache Disorders, 3rd ed. Cephalalgia 38: 1-211, 2018
9）日本頭痛学会・国際頭痛分類委員会（訳）: 国際頭痛分類 第3版. 医学書院, 東京, 2018
10）日本頭痛学会（編）: 慢性頭痛の診療ガイドライン. 医学書院, 東京, 2006
11）日本神経学会, 日本頭痛学会（監修）, 慢性頭痛の診療ガイドライン作成委員会（編）: 慢性頭痛の診療ガイドライン2013. 医学書院, 東京, 2013
12）日本神経学会, 日本頭痛学会, 日本神経治療学会（監修）, 「頭痛の診療ガイドライン」作成委員会（編）: 頭痛の診療ガイドライン2021. 医学書院, 東京, 2021
13）Sakai F, Igarashi H: Prevalence of migraine in Japan: a nationwide survey. Cephalalgia 17: 15-22, 1997
14）Takeshima T, Wan Q, Zhang Y, Komori M, Stretton S, et al: Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain 20: 111, 2019［doi: 10.1186/s10194-019-1062-4］
15）Hirata K, Ueda K, Komori M, Zagar AJ, Selzler KJ, et al: Comprehensive population-based survey of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Curr Med Res Opin 37: 1945-1955, 2021
16）Schulte LH, May A: The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain 139: 1987-1993, 2016
17）Laurell K, Artto V, Bendtsen L, Hagen K, Häggström J, et al: Premonitory symptoms in migraine: a cross-sectional study in 2714 persons. Cephalalgia 36: 951-959, 2016
18）Ueda K, Ye W, Lombard L, Kuga A, Kim Y, et al: Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain 20: 68, 2019［doi: 10.1186/s10194-019-1012-1］
19）Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, et al: Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 randomized clinical trial. JAMA Neurol 75: 1080-1088, 2018［doi: 10.1001/jamaneurol.2018.1212］
20）Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, et al: Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319: 1999-2008, 2018
21）Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, et al: Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology 92: e2309-e2320, 2019［doi: 10.1212/WNL.0000000000007497］
22）Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, et al: Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394: 737-745, 2019
23）Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, et al: Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 397: 51-60, 2021
24）Arca KN, Lambru G, Starling AJ: Neuromodulation in migraine. Handb Clin Neurol 199: 179-200, 2024
25）Dodick DW, Goadsby PJ, Lucas C, Jensen R, Bardos JN, et al: Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment. Cephalalgia 40: 935-948, 2020
26）Lamas Pérez R, Millán-Vázquez M, González-Oria C: Efficacy and safety of galcanezumab as chronic cluster headache preventive treatment under real world conditions: observational prospective study. Cephalalgia 44: 3331024231226181, 2024［doi: 10.1177/03331024231226181］
27）竹島多賀夫: 日本頭痛学会の展望. 第51回日本頭痛学会総会理事長講演. 2023年12月2日
掲載誌情報
